慢性乙型肝炎病毒感染者合并肾、骨损伤的风险及临床管理探讨

摘要/Abstract

摘要： 乙型肝炎病毒(hepatitis B virus, HBV)感染及核苷(酸)类似物治疗会对肾脏和骨骼造成不同程度的损伤,慢性肾脏病、骨质疏松症等肾骨疾病在逐步老龄化的慢性HBV感染者中日益常见,但目前缺乏应对这一问题的系统指导意见。本文意在阐明HBV感染人群的肾骨疾病风险以期引起临床医师对该人群中这两类合并症的重视,并结合指南推荐、临床实际就此人群的肾脏与骨骼健康状况评估、监测及合并肾骨疾病或其风险较高时的抗病毒治疗提出初步建议供借鉴。

关键词: 慢性乙型肝炎, 慢性肾脏病, 骨质疏松症, 核苷(酸)类似物, 替诺福韦

祝胜郎, 肖光明, 韩亚娟, 雷鸣, 关玉娟. 慢性乙型肝炎病毒感染者合并肾、骨损伤的风险及临床管理探讨[J]. 肝脏, 2022, 27(1): 113-115.

参考文献

[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南 (2019年版). 中华肝脏病杂志, 2019, 27: 938-961.
[2] Hou J, Chen W, Han Y, et al. Increasing age and comorbidities in Chinese urban patients with chronic hepatitis B from 2013 to 2016: A retrospective claims data analysis. The 28th Annual Conference of Asian Pacific Association for the Study of the Liver, Manila, Phillipines, Feburary 20-24, 2019.
[3] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC Med, 2018, 16: 93.
[4] Du Y, Zhang S, Hu M, et al. Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China. Medicine, 2019, 98: e14262.
[5] Chen YC, Su YC, Li CY, et al. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan. BMC Nephrol, 2015, 16: 110.
[6] Hong Y S, Ryu S, Chang Y, et al. Hepatitis B virus infection and development of chronic kidney disease: a cohort study. BMC Nephrol, 2018, 19: 353.
[7] Nguyen M H, Lim JK, Burak Ozbay A, et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B. Hepatology, 2019, 69: 959-973.
[8] Wang F, He K, Wang J, et al. Prevalence and risk factors for CKD: A comparison between the adult populations in China and the United States. Kidney Int Rep, 2018, 3: 1135-1143.
[9] Ning L, Lin W, Hu X, et al. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat, 2017, 24: 1043-1051.
[10] Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: A systematic review and meta-analysis. BMC Infect Dis, 2019, 19: 811.
[11] Baeg MK, Yoon SK, Ko SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. Hepatol Int, 2016, 10: 470-477.
[12] Huang Z, Wei H, Cheng C, et al. Low bone mineral density in chronic hepatitis B virus infection: A case-control study. Pak J Med Sci, 2017, 33: 457-461.
[13] Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: A nationwide population-based study. Medicine, 2015, 94: e2276.
[14] Min C, Bang W J, Kim M, et al. The association between hepatitis and osteoporosis: a nested case-control study using a national sample cohort. Arch Osteoporos, 2019, 14: 34.
[15] 国家卫生健康委员会, 国家卫生健康委员会2018年10月19日媒体沟通会文字实录.(2018-10-19)[2020-01-18]. http://www.nhc.gov.cn/wjw/xwdt/201810/d816a5c72f6b45e399a1e7214642cd47.shtml.
[16] Liu A, Le A, Zhang J, et al. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol, 2018, 9: 141.
[17] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017, 67: 370-398.
[18] Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67: 1560-1599.
[19] Kazanciogˇlu R. Risk factors for chronic kidney disease: An update. Kidney Int Suppl, 2013, 3: 368-371.
[20] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med, 2012, 367: 20-29.
[21] KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl, 2013, 3: 1-150.
[22] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol, 2019, 70: 172-193.
[23] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南( 2017). 中华骨质疏松和骨矿盐疾病杂志, 2017, 10: 413-443.
[24] Seto WK, Asahina Y, Brown TT, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection. Clin Gastroenterol Hepatol, 2018.
[25] Udompap P, Kim D, Ahmed A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. Aliment Pharmacol Ther, 2018, 48: 1282-1289.
[26] Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology, 2015, 62: 1318-1320.
[27] Shan S, You H, Niu J, et al. Baseline characteristics and treatment patterns of the patients recruited to the China registry of Hepatitis B. J Clin Transl Hepatol, 2019, 7: 322-328.
[28] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68: 672-681.
[29] Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol, 2020, 5: 441-453.
[30] Janssen H, Lampertico P, Chen CY, et al. SAT429 - Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study. J Hepatol, 2020, 73: S866-S867.